Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4Trastuzumab 3Nivolumab 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2belinostat 2Surveys and Questionnaires 2Sunitinib 2Specimen Handling 2Radiosurgery 2Gemcitabine 2Fluorodeoxyglucose F18 2FAPI-46 2Cisplatin 2130-nm albumin-bound paclitaxel 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1repotrectinib 1relatlimab 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × PLX8394 × Gastrointestinal × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡